New trials and results in systemic treatment of HCC
- PMID: 29653122
- DOI: 10.1016/j.jhep.2018.03.028
New trials and results in systemic treatment of HCC
Abstract
The design of prospective trials in hepatocellular carcinoma is a true challenge because the underlying condition of the liver, upon drug exposure, could interact with the specific course of carcinoma and influence overall outcome. The information generated by basic and clinical researchers provides the rationale for improving the prognosis of this complex disease. However, an additional challenge is interpreting emerging data in real time in order to integrate them into the design of further trials. Analysing recent results in detail may contribute to improving trial design and analysis, expediting the translation of a novel agent's potential benefit, assessed in prospective interventions, to clinical practice. This review summarises the data already known and discusses newly available results, along with ongoing systemic trials in hepatocellular carcinoma treatment.
Keywords: Clinical trials; Hepatocellular carcinoma; Systemic treatment.
Copyright © 2018 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Similar articles
-
Novel therapeutic targets and predictive markers for hepatocellular carcinoma.Expert Opin Ther Targets. 2015 Jul;19(7):973-83. doi: 10.1517/14728222.2015.1031109. Epub 2015 Apr 24. Expert Opin Ther Targets. 2015. PMID: 25910512 Review.
-
Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be?Oncologist. 2006 Jul-Aug;11(7):790-800. doi: 10.1634/theoncologist.11-7-790. Oncologist. 2006. PMID: 16880238 Review.
-
Changing role of histopathology in the diagnosis and management of hepatocellular carcinoma.World J Gastroenterol. 2018 Sep 21;24(35):4000-4013. doi: 10.3748/wjg.v24.i35.4000. World J Gastroenterol. 2018. PMID: 30254404 Free PMC article. Review.
-
Imaging assessment of hepatocellular carcinoma response to locoregional and systemic therapy.AJR Am J Roentgenol. 2013 Jul;201(1):80-96. doi: 10.2214/AJR.13.10706. AJR Am J Roentgenol. 2013. PMID: 23789661 Review.
-
[Advanced hepatocellular carcinoma: importance of clinical trials].Rev Med Suisse. 2015 May 20;11(475):1149-51. Rev Med Suisse. 2015. PMID: 26152091 Review. French.
Cited by
-
Overexpressed DEPDC1B contributes to the progression of hepatocellular carcinoma by CDK1.Aging (Albany NY). 2021 May 25;13(16):20094-20115. doi: 10.18632/aging.203016. Epub 2021 May 25. Aging (Albany NY). 2021. PMID: 34032605 Free PMC article.
-
CD73 promotes hepatocellular carcinoma progression and metastasis via activating PI3K/AKT signaling by inducing Rap1-mediated membrane localization of P110β and predicts poor prognosis.J Hematol Oncol. 2019 Apr 11;12(1):37. doi: 10.1186/s13045-019-0724-7. J Hematol Oncol. 2019. PMID: 30971294 Free PMC article.
-
HKR3 regulates cell cycle through the inhibition of hTERT in hepatocellular carcinoma cell lines.J Cancer. 2020 Feb 10;11(9):2442-2452. doi: 10.7150/jca.39380. eCollection 2020. J Cancer. 2020. PMID: 32201515 Free PMC article.
-
Catalpol inhibits the proliferation, migration and metastasis of HCC cells by regulating miR‑140‑5p expression.Mol Med Rep. 2021 Jan;23(1):29. doi: 10.3892/mmr.2020.11667. Epub 2020 Nov 12. Mol Med Rep. 2021. PMID: 33179108 Free PMC article.
-
ALKBH5 promotes hepatocellular carcinoma cell proliferation, migration and invasion by regulating TTI1 expression.Biomol Biomed. 2024 Sep 6;24(5):1216-1230. doi: 10.17305/bb.2024.10247. Biomol Biomed. 2024. PMID: 38501918 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical